DIA
Drug Information Association Logo

DIA 23rd Annual EuroMeeting Explores New Themes, New Perspectives, and New Synergies

Basel, Switzerland — Jan 03, 2012

DIA in Europe will host the 23rd Annual EuroMeeting from 28-30 March 2011 in Geneva, Switzerland.

DIA’s 23rd Annual EuroMeeting is global in scope, attracting more than 3,000 professionals from over 50 countries. It brings together professionals from the biopharmaceutical industry, contract service organisations, academic research centres, regulatory agencies and health ministries, as well as delegates from patient organisations. The 23rd Annual EuroMeeting features hot topic sessions across 15 themes, including:

  • Innovation, Future of Treatment and Personalised Medicine
  • Securing Approvals in a Changing Environment
  • Patient Safety--From Data Collection and Integration to Benefit/Risk Analysis and Risk Minimisation
  • Clinical Study Endpoints and HTA/Cost Effectiveness
  • Wider Access (Generics/Switching)
  • Engaging the Research World! Pre-Clinical Research and Development
  • Statistics across the Drug Lifecycle
  • Developing Medicines for Special Populations
  • Pharma e-World
  • CMC, Inspection and Assessment, Quality and Counterfeiting
  • Drug/Device Boundary: Is it about to disappear?
  • Global Drug Development in the Real World
  • Biologicals and Vaccines: Access to Innovation
  • Knowledge Management and Telematics: Enhancing Exchange Between Industry and Regulators and Improving Support for Their Decision-Making
  • Pharmaceutical Development--Regional Perspectives

“The landscape of drug development is changing. DIA’s 23rd Annual EuroMeeting will introduce important new themes that will highlight new perspectives on current systems and stimulate discussion on new ways of working and opportunities for new partnerships,” says Programme Co-Chair Valdo Arnera, General Manager, PHT Corporation, Switzerland.

PLENARY SESSION
John Dalli, European Commissioner for Health and Consumer Policy, will deliver the keynote address at the opening plenary on 28 March 2011. He will share his vision for optimising the health of European citizens. 

The plenary session will also include an Oxford Debate on whether or not the current regulatory system supports timely patient access to beneficial medicines.

Moderator:

  • Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency, EU

Debaters:

  • Andrew Dillon, Chief Executive, NICE, UK
  • Peter Bonne Eriksen, Senior Vice President, Global Regulatory Affairs,
  • Novo Nordisk, Denmark
  • Greetje Goossens, Counseler, European Myeloma Platform, The Netherlands
  • Jean Marimbert, Director-General, AFSSAPS, France

Additional EuroMeeting highlights include:

  • Student Sessions
  • Young Professionals Session
  • Heads of Medicines Agencies Session
  • 2015 Roadmap Session
  • Meet the Regulators
  • Joint Swissmedic and WHO Satellite Session

EXHIBITING OPPORTUNITIES
Join more than 200 exhibitors to interact with professionals from the pharmaceutical and device industry, from academia and healthcare, regulatory agencies and patient organisations.

NETWORKING OPPORTUNITIES
Networking is an integral part of the EuroMeeting. Each year, the EuroMeeting offers numerous opportunities to catch up with existing contacts and to make new ones in a relaxing setting. All networking events at the EuroMeeting are included in the registration fee. Networking opportunities include;

La Grande Reception
28 March 2011, 17:30-19:30 at the Ramada Park Hotel

Special Interest Area Communities (SIACs) – Meet and Eat
29 March 2011, 12:30-13:15

Speed Networking Session
29 March 2011, 13:30-14:00

Tuesday Reception
29 March 2011, 17:30-18:30
“This EuroMeeting will ask whether we are really delivering the benefits of new science and technology,” explains Program Co-Chair June Raine, Director, Division of Vigilance Risk Management of Medicines, MHRA, UK. “This year’s event will be a milestone in drug development science, regulatory evolution, stakeholder involvement and partnership working.”

Register for the 23rd Annual EuroMeeting.
View Geneva tourism video.

ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.

Marcel Trachsel, PhD
int/ext Communications AG
+41-61-264 88 00
marcel.trachsel@int-ext.com